203395-81-7

Basic information

• Product Name: Deschloroaripiprazole
• Synonyms: Deschloroaripiprazole;3-Deschloro Aripiprazole;Aripiprazole 3-Deschloro Impurity;7-[4-[4-(2-Chlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone
• CAS NO: 203395-81-7
• Molecular Formula: C23H28ClN3O2
• Molecular Weight: 413.94
• Product Categories: Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 203395-81-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 613.3±55.0 °C(Predicted)
• Appearance: /
• Density: 1.206±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 14.42±0.20(Predicted)
• CAS DataBase Reference: Deschloroaripiprazole(CAS DataBase Reference)
• NIST Chemistry Reference: Deschloroaripiprazole(203395-81-7)
• EPA Substance Registry System: Deschloroaripiprazole(203395-81-7)

Safety Data

• Hazardous Substances Data: 203395-81-7(Hazardous Substances Data)

Usage

Description

Deschloroaripiprazole is a derivative of Aripiprazole (A771000), which is a dopamine D2 receptor agonist. It is primarily known for its antipsychotic properties and is used in the treatment of various psychiatric disorders.

Uses

Used in Pharmaceutical Industry:
Deschloroaripiprazole is used as an antipsychotic agent for the treatment of psychiatric disorders. Its agonist activity on dopamine D2 receptors helps in managing symptoms associated with schizophrenia, bipolar disorder, and other related conditions.
Used in Research Applications:
In the field of neuroscience and pharmacology, Deschloroaripiprazole is used as a research tool to study the role of dopamine D2 receptors in various brain functions and disorders. This helps in understanding the underlying mechanisms of psychiatric conditions and the development of new therapeutic strategies.

Upstream product

• 39512-50-0 N-(o-Chlorophenyl)piperazine 
• 129722-34-5 7-(4-bromobutoxy)-3,4-dihydro-2(1H)-quinolinone 
• 22246-18-0 7-hydroxy-3,4-dihydro-2-(1H)-quinolinone 

Relevant articles and documents

Novel antipsychotic agents with dopamine autoreceptor agonist properties: Synthesis and pharmacology of 7-[4-(4-phenyl-1- piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives

To develop a novel antipsychotic agent which is an agonist of dopamine (DA) autoreceptors and an antagonist of postsynaptic DA receptors, a series of 7-[4-[4-(substituted phenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)- quinolinones was synthesized and their dual activities were examined. The postsynaptic DA receptor antagonistic activities of the compounds were evaluated by their ability to inhibit stereotypy induced by apomorphine in mice, and the autoreceptor agonist activities were determined by their effects on the γ-butyrolactone (GBL)-induced increase in L- dihydroxyphenylalanine (DOPA) synthesis in the mouse brain. Many compounds inhibited the stereotypic behavior, and several compounds reversed the GBL- induced increase in the DOPA synthesis. Among them, 7-[4-[4-(2,3- dichlorophenyl)-l-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone (28, aripiprazole, OPC-14597) was found to have these two activities. This compound reversed the GBL-induced DOPA synthesis (ED50 values of 5.1 μmol/kg po) and inhibited the APO induced stereotypy (ED50 values of 0.6 μmol/kg po). Compound 28 induced catalepsy at 10 times higher dose than that required for the antagonism of APO-induced stereotypy (ED50 value of 7.8 μmol/kg po).